Koru Medical stock price target upgraded, rating held on Q3 report

On Thursday, Piper Sandler, a financial services firm, increased its stock price target for Koru Medical (TASE:PMCN) Systems Inc. (NASDAQ:KRMD) to $3.50, up from the previous target of $3.00. The firm has maintained an Overweight rating on the stock.

This adjustment follows Koru Medical's third-quarter earnings report, which showcased a revenue of $8.2 million, marking a 17% year-over-year increase and surpassing the consensus estimate of $7.7 million. This quarter marks the fourth consecutive time Koru Medical has outperformed expectations.

The revenue beat was primarily attributed to Koru Medical's core U.S. business, which grew faster than the broader immunoglobulin (Ig) market. The company's gross margin percentage finished nearly 350 basis points above the consensus, reflecting robust operational execution. This strong performance prompted the management to raise its 2024 guidance.

According to the analyst's comments, the third quarter was a period of exceptional execution for Koru Medical. The only noted concern was a minor delay related to a 510(k) filing, but otherwise, there were no significant issues raised during the company's conference call.

The analyst's positive outlook on the stock remains intact, with a recommendation for investors to continue buying shares. This recommendation comes even after the stock has seen a rise of more than 30% since early October.

The analyst highlighted Koru Medical's improving track record of execution as the basis for the increased price target. This sentiment reflects confidence in the company's ability to continue delivering strong financial results and operational performance in the future.

In other recent news, Koru Medical Systems reported impressive financial results, with a 22% increase in second-quarter revenues to $8.4 million year-over-year, primarily propelled by its core business and advancements in its Novel Therapies division.

The company also achieved a 65% gross margin for the quarter. Canaccord Genuity recently adjusted its price target for the company, raising it to $4.00 following a strong financial quarter that exceeded both revenue and earnings expectations.

The company has also introduced a Long-Term Incentive Program (LTIP), part of its 2024 Omnibus Equity Incentive Plan, designed to enhance executive retention and performance. The LTIP offers annual equity-based awards to key executives and selected employees.

Despite a delay in its 510(K) submission for next-generation consumables, Koru Medical Systems does not anticipate a significant impact on its revenue projections for 2025. In addition, the company has received regulatory clearance in Japan for its FreedomEdge infusion system and has promoted Chris Pazdan to Chief Operating Officer.

Looking ahead, the company plans to file a 510(K) for a rare disease biologic in tandem with the consumables submission in 2025. Canaccord Genuity's analyst has highlighted the company's potential for sustained momentum, citing its performance in the core subcutaneous immunoglobulin (SCIg) market and its ability to expand. These are the recent developments for Koru Medical Systems.

InvestingPro Insights

Koru Medical Systems Inc. (NASDAQ:KRMD) has been showing strong market performance, aligning with Piper Sandler's optimistic outlook. According to InvestingPro data, the company's stock has seen impressive returns, with a 38.53% price total return over the past three months and a 39.13% return over the past year. This robust performance is reflected in the stock trading near its 52-week high, with the current price at 98.46% of its 52-week peak.

The company's recent financial results are also noteworthy. InvestingPro data shows a quarterly revenue growth of 21.54% in Q2 2024, which supports the strong performance mentioned in the article. Additionally, Koru Medical's gross profit margin stands at a healthy 62.49% for the last twelve months as of Q2 2024, indicating efficient cost management.

InvestingPro Tips highlight that two analysts have revised their earnings upwards for the upcoming period, which aligns with the positive sentiment expressed in the Piper Sandler report. However, it's worth noting that the company is not expected to be profitable this year, and it has not been profitable over the last twelve months. This information provides context to the analyst's focus on revenue growth and operational execution rather than immediate profitability.

For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for KRMD, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.